Non-Hodgkin lymphoma

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas

Retrieved on: 
Monday, June 26, 2023
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Oncology, NHL Enterprises, LP, DNA, Neoplasm, DHL, Lymphoma, Bone marrow, Ibrutinib, NHL, Multimedia, SOC, Non-Hodgkin lymphoma, Bortezomib, Spironolactone, Cell, Article, Machine learning, Mantle cell lymphoma, Patient, Artificial intelligence, Mouse, MCL, FDA, Pharmaceutical industry, Oncotarget, Lantern

Despite advances for NHL using combination and targeted therapies, nearly 20% to 40% of patients with certain subtypes still relapse after treatment.

Key Points: 
  • Despite advances for NHL using combination and targeted therapies, nearly 20% to 40% of patients with certain subtypes still relapse after treatment.
  • “We have developed this molecule from initial ideas to first-in-human clinical testing in a highly efficient and rapid manner by leveraging our AI platform, RADR®.
  • Based on the potential of LP-284 for MCL, Lantern was granted an FDA Orphan Drug Designation for LP-284 in MCL.
  • The full journal article can be found on Lantern’s website or at the Oncotarget website .

Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Retrieved on: 
Friday, June 16, 2023
PTCL, Process, ICML, Non-Hodgkin lymphoma, Lymphoma, CAR, International Conference on Afghanistan, Bonn (2011), Patient, Lymph, TRBC1, Blood, Allogeneic processed thymus tissue, Toxic epidermal necrolysis, CMR, Therapy, Peripheral T-cell lymphoma, Conference, Safety, Vaccine, Pharmaceutical industry

PTCL is a rare and heterogeneous form of non-Hodgkin lymphoma.

Key Points: 
  • PTCL is a rare and heterogeneous form of non-Hodgkin lymphoma.
  • At the cutoff date of April 28, 2023, 19 patients were enrolled into the study and 13 were dosed.
  • Efficacy data from Process B was not provided given median follow up is
  • “There are limited options for patients with PTCL, so new treatments for this aggressive malignancy are desperately needed,” said Dr. Kate Cwynarski, Chief Investigator, UCLH, London.

Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program

Retrieved on: 
Thursday, June 15, 2023
Diamond, Immune reconstitution inflammatory syndrome, Volunteering, Fortress Biotech, City of Hope, HIV, Cytomegalovirus, NCT, CMV, NIH, Immunity, Opportunistic infection, HCT, American Journal of Hematology, Bangladesh Technical Education Board, Transplant, National Cancer Institute, Non-Hodgkin lymphoma, City, Patient, Risk, Haematopoietic system, Viral load, Mortality, Research, NCI, Safety, Vaccine, Triplex, Hematology

MIAMI, June 15, 2023 (GLOBE NEWSWIRE) -- Helocyte, Inc. (“Helocyte”), a subsidiary company of Fortress Biotech, Inc. (Nasdaq: FBIO), today announced that the National Cancer Institute (“NCI”) has awarded a $3.22 million grant to City of Hope for clinical studies of Triplex, a cytomegalovirus (“CMV”) vaccine being developed by Helocyte and City of Hope. This competitive award will fund two planned multicenter, placebo-controlled, randomized Phase 2 studies to evaluate the potential safety and immunological response of Triplex and its ability to enhance CMV-specific T cell immunity in stem cell donors to reduce the risk of CMV events in recipients of allogeneic hematopoietic cell transplant (“HCT”). Triplex was initially developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.

Key Points: 
  • Triplex was initially developed by City of Hope , one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.
  • Diamond and his team developed Triplex and he serves as a consultant to Helocyte.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
  • Helocyte will provide clinical materials to support the trial.

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

Retrieved on: 
Wednesday, June 14, 2023
Lymphoma, CD79B, Central nervous system, University, PD, Chronic lymphocytic leukemia, Cytarabine, SC1, Follicular lymphoma, Lymphoid leukemia, Half-life, DLBCL, Hematology, ICML, IMCL, Non-Hodgkin lymphoma, Survival, Pharmacokinetics, Head, Absorption, BTK, CNS, Etoposide, International Conference on Emerging Infectious Diseases, Primary central nervous system lymphoma, Patient, UCSF, American Society of Hematology, Mantle cell lymphoma, SAN, Memorial Sloan Kettering Cancer Center, AUC, Mouse, Bone marrow, MCL, Therapy, Poster, Society, Conference, Safety, Vaccine, Pharmaceutical industry, Cmax

SAN FRANCISCO, June 14, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced the presentation of clinical and preclinical data from its targeted protein degradation programs, NX-5948 and NX-2127, which are being evaluated in ongoing Phase 1 clinical trials in patients with relapsed/refractory B cell malignancies. These data are being presented at the 17th International Conference on Malignant Lymphoma (ICML) which is being held June 13-17, in Lugano, Switzerland.

Key Points: 
  • These data are being presented at the 17th International Conference on Malignant Lymphoma (ICML) which is being held June 13-17, in Lugano, Switzerland.
  • Limitations of current covalent and non-covalent BTK inhibitors include the susceptibility to mutational escape as a basis for resistance.
  • Nurix’s BTK degraders have the potential to address these limitations of BTK inhibitors and provide a new therapeutic option for patients.
  • Nurix is announcing plans to initiate two new Phase 1b dose expansion cohorts in the ongoing Phase 1a/1b clinical trial of NX-2127 in patients with relapsed or refractory B-cell malignancies.

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

Retrieved on: 
Friday, June 9, 2023
Online, Lymphoma, Neutropenia, Abstract, Wiley (publisher), Diffuse large B-cell lymphoma, DLBCL, European Hematology Association, Non-Hodgkin lymphoma, OH, Doctor of Philosophy, Gamma-glutamyltransferase, B-cell lymphoma, ORR, Medical College of Wisconsin, International Conference on Conceptual Modeling, CEST, Ira Middleswarth & Son, Inc., EHA, CR, Pivotal, ADC, Therapy, NYSE, Thrombocytopenia, Conference, Safety, Disease, Pharmaceutical industry, Book, MD, Patient, Gallery

LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Key Points: 
  • LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
  • “We’re pleased to be sharing updated LOTIS-2 results demonstrating the long‐term efficacy and safety of ZYNLONTA with the lymphoma community at EHA2023 and 17-ICML,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • The median (range) time to response was 41.0 (35 to 247) days for all responders and 42.0 (36 to 247) days for patients with a CR.
  • All-grade treatment‐emergent adverse events occurring in ≥30% of all patients were increased gamma-glutamyltransferase (42%), neutropenia (40%), and thrombocytopenia (33%).

Acepodia Secures $100 Million Series D Financing to Advance

Retrieved on: 
Tuesday, June 6, 2023
ACC, Nobel Prize, Genetic engineering, Nobel Prize in Chemistry, Venture round, Cancer, CD20, Research, Click chemistry, Hematological Cancer Research Investment and Education Act, Patient, Non-Hodgkin lymphoma, Venture capital financing, Vaccine, Chemistry

ALAMEDA, Calif. and TAIPEI, June 6, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, today announced a $100 million Series D financing led by Digital Mobile Venture with participation from additional existing investors. The funds will be used to progress the company's pipeline of enhanced cell therapies for solid tumors and hematologic cancers, including ACE1831 and ACE2016. ACE1831 is an anti-CD20 armed allogeneic gamma delta 2 T-cell therapy currently being studied in a Phase 1 trial for patients with non-Hodgkin Lymphoma. ACE 2016 is an anti-EGFR armed allogeneic gamma delta 2 T-cell therapy targeting EGFR-expressing solid tumors.

Key Points: 
  • ACE1831 is an anti-CD20 armed allogeneic gamma delta 2 T-cell therapy currently being studied in a Phase 1 trial for patients with non-Hodgkin Lymphoma.
  • "This financing illustrates the confidence of Acepodia's current investors in our team, our mission, and our differentiated platform, and we are extremely grateful for their support," said Sonny Hsiao, Ph.D., chief executive officer of Acepodia.
  • Acepodia has raised $259 million to date in venture capital financing, including a $109 million Series C round completed in December 2021.
  • Returning investors in the Series D included Digital Mobile Venture as the lead investor.

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

Retrieved on: 
Tuesday, May 23, 2023
PTCL, CET, ASH, Brentuximab vedotin, DOR, Clinical trial, NHL, Cancer, NK, Hodgkin lymphoma, CHL, EDT, CFGB-FM, MD Anderson Cancer Center, Running, Cytokine release syndrome, Patient, University, HL, CR, Non-Hodgkin lymphoma, Webcast, Diagnosis, PD-1, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Society, ORR, Food, Safety, Vaccine, Pharmaceutical industry, Affimer

The phase 2 study will be an open-label, multi-center, multi-cohort study with a safety run-in followed by dose optimization and expansion phases.

Key Points: 
  • The phase 2 study will be an open-label, multi-center, multi-cohort study with a safety run-in followed by dose optimization and expansion phases.
  • The study will evaluate the safety and efficacy of AFM13 in combination with AB-101 in patients with r/r cHL and CD30-positive PTCL.
  • Affimed intends to initiate the study in the third quarter of 2023 and expects to report data from the safety run-in phase in the first half of 2024.
  • During the IND process, Affimed requested FDA feedback on the suitability of the study to support an accelerated approval in cHL.

Lunsumio™, Jaypirca™ Available at AllianceRx Walgreens Pharmacy for Treatment of Two Forms of Non-Hodgkin Lymphoma

Retrieved on: 
Wednesday, May 17, 2023
Lymphoma, NHL, Tissue, Hodgkin lymphoma, Pharmacy, Pirtobrutinib, Follicular lymphoma, Lymphatic system, Non-Hodgkin lymphoma, Cancer, Bristol Myers Squibb, Genentech, BTK, Pharmacist, Psoriasis, Eli Lilly, Light, Patient, Lymph, Mantle cell lymphoma, Mosunetuzumab, MCL, Health, Roche, Pharmaceutical industry

ORLANDO, Fla., May 17, 2023 /PRNewswire/ -- AllianceRx Walgreens Pharmacy, one of the largest specialty and home delivery pharmacies in the U.S., will now distribute two medications indicated for adults with certain types of lymphoma.

Key Points: 
  • ORLANDO, Fla., May 17, 2023 /PRNewswire/ -- AllianceRx Walgreens Pharmacy , one of the largest specialty and home delivery pharmacies in the U.S., will now distribute two medications indicated for adults with certain types of lymphoma.
  • "Patients living with lymphoma or any cancer not only deserve access to the therapies they need, but also the support to help them throughout their treatment journey.
  • AllianceRx Walgreens Pharmacy also has access to Sotyktu™ (deucravacitinib).
  • Manufactured by Bristol Myers Squibb, Sotyktu treats moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio

Retrieved on: 
Wednesday, May 17, 2023
Biotechnology, Genetics, Health, Oncology, Antigen, Gene, The central science, CBLB, Neoplasm, Non-Hodgkin lymphoma, Cancer, NSG, Toxicity, American Society of Gene and Cell Therapy, TCR, Acute myeloid leukemia, CAR, Patient, Annual general meeting, Cell, Canadian Aviation Regulations, Immunosuppression, Society, Vaccine

(Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced new data featuring novel approaches combining the company’s platform CAR T cell and T cell receptor technology and unique cell therapy engineering capabilities to potentially enhance treatment potency in a range of cancers.

Key Points: 
  • (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced new data featuring novel approaches combining the company’s platform CAR T cell and T cell receptor technology and unique cell therapy engineering capabilities to potentially enhance treatment potency in a range of cancers.
  • The data were shared in three presentations at this year’s American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Los Angeles, California.
  • “We’re excited to present new data related to our programs in acute myeloid leukemia, non-Hodgkin lymphoma and solid tumors,” said Philip Gregory, D.Phil., chief scientific officer, 2seventy bio.
  • “These presentations provide further evidence of our focus on generating potent and targeted anti-tumor activity while limiting toxicity through innovative approaches to controlling T cell responses.

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, May 11, 2023
AACR, CD19, European Hematology Association, ADCC, Non-Hodgkin lymphoma, Lymphoma, Cyclophosphamide, G&A, NK, Antibody, Doctor of Philosophy, CAR, AML, Asilomar International Conference on Climate Intervention Technologies, Patient, Investment, The Retreat, Cytarabine, EHA, R, Research, Conference, NKG2D, Safety, D, Pharmaceutical industry, Vaccine, Cash

Cash and Cash Equivalents: As of March 31, 2023, Nkarta had cash, cash equivalents, restricted cash, and investments of $332.1 million.

Key Points: 
  • Cash and Cash Equivalents: As of March 31, 2023, Nkarta had cash, cash equivalents, restricted cash, and investments of $332.1 million.
  • Non-cash stock-based compensation expense included in R&D expense was $2.1 million for the first quarter of 2023.
  • Non-cash stock-based compensation expense included in G&A expense was $2.7 million for the first quarter of 2023.
  • Net Loss: Net loss was $30.8 million, or $0.63 per basic and diluted share, for the first quarter of 2023.